12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Dolutegravir regulatory update

ViiV submitted regulatory applications in the U.S., EU and Canada for dolutegravir to treat HIV infection in patients ages >=12 years. The submissions include data from the Phase III VIKING-3 and SAILING trials in treatment-experienced patients as well as...

Read the full 171 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >